Press releases

* (R) = Regulatory press releases

Feb 13, 2025

Invitation to presentation of Cantargia’s Year-End report 2024
Feb 5, 2025

(R) Cantargia announces management changes
Jan 31, 2025

(R) Cantargia announces changes in number of shares and votes
Dec 23, 2024

(R) Cantargia announces outcome of the rights issue
Dec 18, 2024

Cantargia publishes strong preclinical effects and clinical monotherapy results on nadunolimab in pancreatic cancer in Journal for Immunotherapy of Cancer
Dec 11, 2024

Cantargia and GEICAM present updated phase 1 clinical data and new translational results on nadunolimab treatment in advanced triple negative breast cancer at San Antonio Breast Cancer Symposium
Dec 4, 2024

(R) Cantargia publishes prospectus in connection with rights issue
Dec 2, 2024

(R) Extraordinary general meeting in Cantargia AB (publ)
Nov 29, 2024

(R) Cantargia expands the CAN10 phase 1 clinical program building on positive results
Nov 15, 2024

(R) Cantargia publishes interim report for third quarter 2024
<< Newer press releases    Older press releases >>

In media

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye

CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden

E-mail: info@cantargia.com
Switch board: +46(0)46 2756260

Privacy Policy

Subscribe to our press releases

© Copyright 2026 · Cantargia AB